Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated (Nasdaq: CYTK) is a specialty cardiovascular biopharmaceutical company that regularly issues news about its medicines and programs in cardiac muscle dysfunction. Company updates frequently highlight MYQORZO (aficamten), a cardiac myosin inhibitor that Cytokinetics reports is approved in the United States and China for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, as well as related regulatory developments in other regions.
News for CYTK often covers key regulatory milestones such as positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency, approvals by national regulatory agencies and progress of New Drug Application reviews. Cytokinetics also reports on clinical trial data from studies like SEQUOIA-HCM and MAPLE-HCM, including results presented at major cardiology congresses and publications in peer-reviewed journals.
Investors and observers can find announcements about the company’s broader pipeline, including omecamtiv mecarbil in heart failure with severely reduced ejection fraction, ulacamten in heart failure with preserved ejection fraction and CK-089 in skeletal muscle disorders. Additional news items describe financial results, capital raising activities, inducement equity grants, executive appointments and participation in healthcare and investor conferences.
This CYTK news page aggregates these disclosures so readers can follow developments in Cytokinetics’ cardiovascular programs, regulatory interactions and corporate activities over time.
Cytokinetics (CYTK) has scheduled its fourth quarter 2024 financial results announcement for February 27, 2025, at 4:00 PM Eastern Time. The announcement will be followed by a conference call at 4:30 PM Eastern Time, where senior management will discuss operational and financial results along with the company's future outlook.
The conference call will be accessible through a simultaneous webcast from the Investors & Media section of Cytokinetics' website. Participants can also join via telephone by pre-registering through a provided link. A replay of the webcast will remain available on the company's website for six months.
Cytokinetics (NASDAQ: CYTK) has appointed Robert E. Landry to its Board of Directors, bringing over three decades of pharmaceutical industry financial and operational expertise. Landry most recently served as Chief Financial Officer at Regeneron Pharmaceuticals for 11 years, where he managed financial operations, investor relations, IT, competitive intelligence, and global facilities.
During his tenure at Regeneron, Landry oversaw two public acquisitions (Checkmate Pharmaceuticals and Decibel Therapeutics) and helped establish global affiliates as the company experienced substantial market capitalization and workforce growth. Previously, he spent 25 years at Wyeth and Pfizer in various roles including Corporate Treasurer and CFO of Wyeth Australia and New Zealand.
The appointment comes as Cytokinetics approaches potential approval and launch of its first medicine, with the company aiming to become a fully integrated organization focused on sustainable growth.
Cytokinetics (Nasdaq: CYTK) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President and Chief Executive Officer, Robert I. Blum, will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 4:40 PM Eastern Time.
Interested participants can access the live webcast through the Investors & Media section of Cytokinetics' website. Following the event, the webcast recording will remain accessible on the company's website for a 90-day period.
Cytokinetics (CYTK) has announced inducement grants to 13 new employees who joined in January 2025. The grants include:
- 64,587 stock options at $49.46 per share (closing price on January 31, 2025), vesting over 4 years with a 10-year term
- 41,939 restricted stock units (RSUs) vesting over 3 years (40% in year 1, 40% in year 2, 20% in year 3)
- 6,066 performance stock units (PSUs) tied to two performance goals
The PSUs will be earned based on achievement of two performance goals, with 50% of earned shares vesting upon Committee certification and the remaining 50% one year later. All grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.
Cytokinetics (NASDAQ: CYTK) has announced the recipients of its seventh annual Communications Grant Program, awarding a total of $100,000 to five patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure communities. Each organization received $20,000 to support communications, awareness building, and community engagement initiatives.
The 2025 grant recipients include AICARM APS (Italian Association of Cardiomyopathies), HeartBrothers Foundation, HeartCharged , Hypertrophic Cardiomyopathy Association (HCMA), and Stichting Cardiomyopathie Onderzoek Nederland. The funds will support various projects including educational video production, patient quality of life assessments, short films about HCM patient experiences, digital partnerships, and qualitative research to improve patient and healthcare professional engagement.
Cytokinetics (CYTK) has initiated AMBER-HFpEF, a Phase 2 clinical trial for CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF). The study is designed as a randomized, placebo-controlled, double-blind, multi-center, dose-finding trial, specifically targeting patients with LVEF ≥60%.
CK-586, a cardiac myosin inhibitor, is being developed to treat a subgroup of HFpEF patients with hypercontractility and ventricular hypertrophy. The trial's focus on HFpEF patients is significant as approximately half of heart failure patients have this condition, characterized by ejection fraction ≥50%, impaired diastolic function, and elevated NTpro-BNP.
The development strategy builds on similarities between a subset of HFpEF patients and those with non-obstructive hypertrophic cardiomyopathy (nHCM), leveraging data from aficamten in nHCM.
Cytokinetics (CYTK) has announced its 2025 milestones and Vision 2030 strategic plan. The company anticipates a PDUFA target action date of September 26, 2025 for aficamten, its cardiac myosin inhibitor for obstructive HCM. Key 2025 milestones include preparing for aficamten's U.S. commercial launch in 2H 2025, expanding European commercial readiness for potential EMA approval in 1H 2026, and supporting potential approval in China in 2H 2025.
The company will report topline results from MAPLE-HCM Phase 3 trial in 1H 2025, complete enrollment for ACACIA-HCM Phase 3 trial and CEDAR-HCM pediatric trial in 2H 2025. Additionally, Cytokinetics continues patient enrollment in COMET-HF for omecamtiv mecarbil and plans to complete enrollment of initial cohorts in AMBER-HFpEF for CK-586.
Vision 2030 objectives include advancing two approved products across three indications, developing ten novel molecular entities, reaching over 100,000 patients globally, and expanding access to medicines in more than 15 countries throughout North America and Europe.
Cytokinetics (CYTK) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Robert I. Blum, will deliver a presentation on Monday, January 13, 2025, at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco.
Interested investors and stakeholders can access the presentation through a live webcast available on the Investors & Media section of the Cytokinetics website. The recording will remain accessible on the company's website for 90 days following the event's conclusion.
Cytokinetics (CYTK) has announced inducement grants to 9 new employees who joined in December 2024. The grants include:
- 52,188 stock options at $47.04 per share (closing price on Dec 31, 2024), vesting over 4 years with 1/4th after first year and 1/48th monthly thereafter
- 33,885 restricted stock units (RSUs) vesting over 3 years (40% after year 1, 40% after year 2, 20% after year 3)
- 3,189 performance stock units (PSUs) tied to two performance goals, with 50% of earned shares vesting upon goal certification and 50% one year later
All grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment, subject to continued service requirements.
Cytokinetics (CYTK) announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for aficamten, a cardiac myosin inhibitor designed to treat obstructive hypertrophic cardiomyopathy (HCM). The application will be reviewed by the Committee for Medicinal Products for Human Use (CHMP).
The MAA is supported by results from the SEQUOIA-HCM Phase 3 clinical trial, published in the New England Journal of Medicine. This follows the FDA's acceptance of aficamten's New Drug Application (NDA) in the US, which has a PDUFA target action date of September 26, 2025. The drug is also under regulatory review in China.